Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury.

Holditch SJ, Brown CN, Lombardi AM, Nguyen KN, Edelstein CL. · 2019

Read Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury. by Holditch SJ, Brown CN, Lombardi AM, Nguyen KN, Edelstein CL. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6627318.txt.

Introduction

Holditch and co-authors review recent advances on kidney injury from cisplatin. Their article appears in the International Journal of Molecular Sciences. Cisplatin treats many solid tumors and reaches 10 to 20% of cancer patients. Acute kidney injury strikes about 30% of those who receive it. That harm caps how much drug doctors can give.

The review leans on rodent models that mirror the human injury. Transporters pull cisplatin into kidney tubule cells, where it builds up. Cell death, inflammation, and oxidative stress then unfold. Standard markers such as creatinine can miss mild injury. Newer markers include NGAL, KIM-1, and cystatin C. The authors cover magnesium protection and transporter-based strategies. They also flag the dose gap between mouse studies and patient care.

Catalog record

CREATORHolditch SJ, Brown CN, Lombardi AM, Nguyen KN, Edelstein CL.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE104 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6627318

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury By Sara J Holditch, Carolyn N Brown, Andrew M Lombardi, Khoa N Nguyen, Charles L Edelstein Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms20123011 ABSTRACT Abstract Cisplatin is a widely used chemotherapeutic agent used to treat solid tumours, such as ovarian, head and neck, and testicular germ cell. A known complication of cisplatin administration is acute kidney injury (AKI). The development of effective tumour interventions with reduced nephrotoxicity relies heavily on understanding the molecular pathophysiology of cisplatin-induced AKI. Rodent models have provided mechanistic insight into the pathophysiology of cisplatin-induced AKI. In the subsequent review, we provide a detailed discussion of recent advances in the cisplatin-induced AKI phenotype, principal mechanistic findings of injury and therapy, and pre-clinical use of AKI rodent models. Cisplatin-induced AKI murine models faithfully develop gross manifestations of clinical AKI such as decreased kidney function, increased expression of tubular injury biomarkers, and tubular injury evident by histology. Pathways involved in AKI include apoptosis, necrosis, inflammation, and increased oxidative stress, ultimately providing a translational platform for testing the therapeutic efficacy of potential interventions. This review provides a discussion of the foundation laid by cisplatin-induced AKI rodent models for our current understanding of AKI molecular pathophysiology. Keywords: cisplatin, acute kidney injury, AKI, apoptosis, inflammation, oxidative stress 1. INTRODUCTION Cis-diamminedichloroplatinum(II) (cisplatin) is an inorganic platinum derivative used to treat several types of cancer including bladder, ovarian, lung, and testicular [1]. Cisplatin is prescribed to 10–20% of all cancer patients due to its efficacy in slowing cancer growth. Renal uptake and excretion of cisplatin is mediated by proximal tubule localized transporters, such as OCT2 and MATE1. Consequently, cisplatin accumulates in renal proximal tubular cells, resulting in inflammation, injury, and cell death [2]. Acute kidney injury (AKI) is the principal limitation for cisplatin cancer treatment, affecting 30% of cisplatin recipient patients. AKI is clinically defined by a decline in kidney function that manifests as a ≥0.3 mg/dL increase in serum creatinine or a 0.5 mL/kg/h decrease in urine output [3]. Several additional biomarkers, such as NGAL, KIM-1, and Cystatin-C, are routinely used to detect AKI in both patients and animal models [4], but are not always reliable indicators of AKI, as they are less sensitive to mild cases of kidney injury [5] and present differently based on factors such as age [6], sex, and patient comorbidities. Despite several positive treatment studies in rodents, the prevalence of cisplatin-induced AKI in patients remains high, for several possible reasons. The goal of cisplatin dosing regimens in patients is to slow cancer growth while limiting off-target side effects, such as nephrotoxicity. Rodents are purposely given large doses of cisplatin with the intent of causing severe and easily detectable AKI (i.e., significant increase of current known biomarkers). Thus, there is a discrepancy between the manifestation of AKI in humans versus mouse models. Therefore, it is crucial to identify novel biomarkers of AKI, refine animal models, and identify new molecular targets for treatment. Recently, the field has expanded on the types of cisplatin-induced AKI models utilized, the pathomechanism of cisplatin-induced injury unique to reactive oxygen species and mitochondrial dysfunction, pathways of cell death, inflammatory responses, autophagy, and the role of Klotho in AKI [7,8,9,10,11,12,13,14,15,16,17,18,19]. 1.1. Cellular Import and Export Mechanisms Cellular uptake of cisplatin is mediated by basolaterally-localized influx transporters such as organic cation transporters (OCTs) and copper transporters (CTRs) [20]. Cisplatin secretion into the urine is mediated by apically-localized efflux transporters, such as multidrug resistance-associated proteins (MRPs), multi-antimicrobial extrusion protein (MATEs) [21], and ATPases [20,22]. These transporters are highly expressed in the proximal and distal tubules of the kidneys [23]. Aberrant expression and localization of cisplatin transporters in response to cisplatin administration has been reported in recent studies of cisplatin-AKI [21]. Inhibition of cisplatin influx transporters or activation of cisplatin efflux transporters have been popular strategies for reducing cisplatin-induced AKI. For example, cimetidine has been postulated to protect against nephrotoxicity by competitively inhibiting cisplatin transport via OCT2 in kidney cells, however this theory has been discredited in in vitro experiments in Madin-Darby Canine Kidney (MDCK) cells [24]. It should be noted, however, that inhibition of transporters that are also expressed in cancer cells may decrease the anti-cancer properties of cisplatin. Thus, it is important to use tumour bearing mouse models to test the renoprotective effects of therapies targeting cisplatin transporters. Magnesium is a key regulator of expression of cisplatin transporters [25]. Cisplatin decreases serum magnesium [26]. Magnesium deficiency increases AKI severity [27] by decreasing expression of efflux transporters and allowing for cisplatin accumulation in tubular cells [28,29]. Kumar et al. recently showed that magnesium supplementation protected against AKI and did not interfere with the anti-tumour effects of cisplatin [27]. In conclusion, administration of cisplatin is shown to change expression of cisplatin transporters. Decreasing expression of influx transporters and increasing expression of efflux transporters is shown to protect against cisplatin-induced AKI. Targeting cisplatin transporters presents challenges, such as maintenance of the anti-tumour efficacy of cisplatin. However, targeting the renal uptake and excretion is an attractive therapeutic target as it allows for intervention before development of tubular injury by dysregulated intracellular signaling. 1.2. Cisplatin-Induced AKI Mouse Models 1.2.1. Non-Tumour Bearing Current research in cisplatin-induced AKI utilizes primarily two murine models, the short-term high dose [2], and long-term low dose nephrotoxic mouse models [30]. For example, the long-term model uses 5–15 mg/kg cisplatin administration, administered 2–4 times, over a period of 3–4 weeks [30]. The short-term model uses a single high dose of cisplatin, 20–30 mg/kg, that results in mortality and nephrotoxicity at 3–7 days post-cisplatin-induced AKI [2]. Many of these models rely heavily on male, young, 6–10 week, C57BL/6 mice. However, female C57BL/6 mice have a documented higher propensity for increased AKI severity after cisplatin injection [5]. Further, aged mice, 16–17 months of age, also demonstrate worse cisplatin-induced AKI compared to younger controls [6]. Even strain variance has influenced the development and severity of AKI [31,32]. Irrespective of the model, cisplatin-induced AKI is routinely measured using serum creatinine, BUN, Cystatin-C, KIM-1, NGAL, CCL2, and IL-18 (Table 1). Interestingly, novel biomarkers, such as renal specific miRNAs, have been described in cisplatin-induced AKI (Table 1). MiRNAs are useful in detecting cisplatin-induced AKI because they show increases in the urine after 18 h, which is faster than creatinine or BUN [4]. Biomarkers may provide utility in detecting AKI with high sensitivity and specificity, prior to decreased kidney function. [Table: Routine and novel biomarkers of cisplatin-induced AKI.] 1.2.2. Tumour Bearing Models The two most common cisplatin-induced AKI models discussed above are by and large the work horse of understanding the pathomechanism of cisplatin-induced inflammation, apoptosis, reactive oxygen species, and cell populations mediating inflammation. Though informative, neither of these two models reflect the clinical reality for patients [53]. For example, cisplatin is administered chronically, at doses less than 10 mg/kg in patients [30], in order to treat solid tumours. Yet, rarely are mice consistently administered less than 10 mg/kg of cisplatin, nor do studies incorporate tumour bearing mice. While the critique on dosing simplifies the technical reality that certain strains of mice may be more resistant to nephrotoxic substances [54], necessitating non-clinically relevant doses to produce clinically relevant cisplatin AKI phenotypes,

Read the complete text